P&G (PG) Reports Q4 Earnings: What Key Metrics Have to Say

Procter & Gamble (PG) reported Q4 2025 results, with revenue of $20.89 billion (+1.7% YoY) and EPS of $1.48, both exceeding analyst consensus estimates. The company's total organic sales growth of 2% surpassed the 1.4% analyst forecast, signaling robust underlying performance. However, several key segments, including Beauty, Grooming, Fabric & Home Care, and Health Care, missed their individual organic sales growth estimates. Despite the positive headline figures, PG shares have underperformed the S&P 500 over the past month, returning -1.4% against the index's +3.6%.

Analysis

Procter & Gamble's Q4 2025 results present a mixed operational picture, characterized by headline beats that conceal underlying weakness in key operating segments. The company reported revenue of $20.89 billion, a 1.7% year-over-year increase, and an EPS of $1.48, surpassing consensus estimates by 0.39% and 3.5% respectively. Total organic sales growth of 2% also exceeded the 1.4% analyst forecast, suggesting some pricing power or volume strength at an aggregate level. However, a granular review of segment performance reveals that this growth was not broad-based. Organic sales growth in the Grooming segment was notably weak at 1%, falling significantly short of the 2.8% consensus estimate, while the Health Care segment's 2% growth also missed the 3.1% forecast. This uneven performance indicates that while the company met its overall targets, potentially supported by a beat in Baby Care and a 35.6% YoY surge in 'Corporate' net sales, core consumer demand in several key categories may be decelerating. This fundamental ambiguity is reflected in the stock's recent market underperformance, having returned -1.4% over the past month while the S&P 500 composite gained 3.6%, suggesting investors are pricing in this muted growth profile despite the positive earnings surprises.

Key Decisions for Investors

• Investors should look past the headline revenue and EPS beats and focus on the softness in organic sales growth for key segments like Grooming, Health Care, and Beauty, as this may signal a deceleration in core consumer demand.
• Given the stock's recent underperformance against the S&P 500 despite positive earnings surprises, investors should consider that the market may already be pricing in a low-growth environment and segment-specific headwinds.
• The mixed results and neutral Zacks Rank #3 (Hold) warrant a cautious stance; it may be prudent to await forward-looking guidance or signs of a reacceleration in the lagging segments before increasing exposure.